Related Experiment Video

Updated: Jul 11, 2026

Randomized Controlled Trial to Study the Acute Effects of Strength Exercise on Insulin Sensitivity in Obese Adults
06:13

Randomized Controlled Trial to Study the Acute Effects of Strength Exercise on Insulin Sensitivity in Obese Adults

Published on: December 1, 2023

Thiazolidinediones: effects on insulin resistance and the cardiovascular system

C E Quinn1, P K Hamilton, C J Lockhart

  • 1Department of Therapeutics and Pharmacology, Queen's University Belfast, Belfast, UK. cathyquinn25@hotmail.com

British Journal of Pharmacology
|October 2, 2007
PubMed

Insights

Thiazolidinediones (TZDs) improve insulin sensitivity and may delay type 2 diabetes. While beneficial for cardiovascular risk factors, their impact on actual cardiovascular events and safety profiles require further investigation.

Area of Science:

  • Pharmacology
  • Endocrinology
  • Cardiology

Background:

  • Thiazolidinediones (TZDs) are established treatments for hyperglycemia in type 2 diabetes.
  • They function as peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists, primarily in adipose tissue.
  • TZDs have demonstrated potential in delaying diabetes onset and improving cardiovascular risk factors.

Purpose of the Study:

  • To review the mechanisms of action of TZDs.
  • To evaluate their clinical effects on insulin sensitivity and cardiovascular risk markers.
  • To discuss the evidence regarding their impact on cardiovascular events and safety.

Main Methods:

  • Review of existing literature on TZD pharmacology and clinical trials.
  • Analysis of studies investigating PPAR-gamma activation and its downstream effects.
  • Examination of data on cardiovascular outcomes and safety profiles of TZDs.

Main Results:

  • TZD activation of PPAR-gamma enhances insulin sensitivity by increasing fatty acid uptake and adiponectin production, while reducing inflammatory mediators (TNF-alpha, PAI-1, IL-6).
  • Clinical studies show TZDs can reduce atherosclerosis markers like carotid intima-media thickness (CIMT).
  • Despite improvements in risk markers, TZDs have not definitively reduced cardiovascular events, and concerns exist regarding rosiglitazone safety.

Conclusions:

  • TZDs improve insulin sensitivity and show promise in managing type 2 diabetes and cardiovascular risk factors.
  • Further research is needed to confirm their efficacy in reducing cardiovascular events and to fully ascertain their long-term safety.
  • Dual PPAR-alpha/gamma agonists present a potential alternative but require rigorous safety evaluations.

More Related Videos

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Antihypertensive Drugs: Thiazide-Class Diuretics01:15

Antihypertensive Drugs: Thiazide-Class Diuretics

Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...